RCKT earnings analysis
What we found in RCKT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include income-statement, segment, balance-sheet working-capital, or cash-flow statement data, so revenue, margins, EPS, operating cash flow, and free cash flow trends cannot be assessed. Liquidity improved, with cash, cash equivalents and investments rising to $283.7 million from $188.9 million at year-end 2025. The principal negative is ongoing securities and derivative litigation, while management reported effective disclosure controls and no material internal-control changes. No quantitative financial guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Liquidity increased materially
- Cash, cash equivalents and investments increased to $283.7 million at June 30, 2026 from $188.9 million at December 31, 2025, a $94.8 million increase.
- Limited disclosed interest-rate sensitivity
- The company’s investments are primarily in U.S. Treasury securities, and a 100-basis-point immediate increase in interest rates would have produced a hypothetical $0.1 million decline in net fair value.
- Disclosure controls deemed effective
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
- No material control changes
- The company reported no changes in internal control over financial reporting during the period that materially affected, or were reasonably likely to materially affect, those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Consolidated securities litigation
- Two securities class actions filed on June 11, 2025 and July 18, 2025 were consolidated; the amended complaint covers investors who acquired securities from February 28, 2024 through August 25, 2025. The company cannot predict the outcome or estimate a potential loss.
- Derivative action and legal costs
- A putative derivative action filed on October 22, 2025 remains stayed pending resolution of motions to dismiss the securities litigation; the company will pay legal fees related to the action and cannot estimate potential loss.
- Unhedged investment-rate exposure
- The company has $283.7 million of cash, cash equivalents and investments exposed to interest-rate changes, does not use interest-rate hedges, and estimates a $0.1 million fair-value decline from a 100-basis-point rate increase.
What they said about what is next.
No quantitative financial guidance or outlook was provided in the supplied 10-Q text. The filing states that material risk factors were disclosed in the 2025 Form 10-K and that there had been no material changes.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Rocket Pharmaceuticals reported a significant decrease in operating expenses for Q1 2026, with R&D expenses down by $4.5 million to $31.5 million compared to Q1 2025. The net loss narrowed to $47.6 million from $61.3…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RCKT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever